Literature DB >> 3396145

Dose-dependent pharmacokinetics of flavone acetic acid in mice.

G Damia1, M L Zanette, C Rossi, R Mandelli, A Ferrari, M D'Incalci.   

Abstract

The pharmacokinetics of the novel anticancer agent, flavone acetic acid (FAA) were investigated in Balb-c mice treated with i.v. doses of 100 mg/kg or 300 mg/kg, using an HPLC assay. The kinetics of disappearance from plasma was monoexponential and dose-dependent. After 100 mg/kg, the plasma peak level was 250 +/- 11 micrograms/ml, t1/2 was 0.5 h, and AUC was 309 micrograms/ml per h. After 300 mg/kg, the plasma peak level was 710 +/- 57 micrograms/ml, t1/2 was 2.1 h, and the area under the curve (AUC) 1771 micrograms/ml h. Mouse plasma protein binding of FAA was about 70%. As is the case with plasma, in all tissues analyzed, the FAA-AUC values were disproportinately greater after 300 mg/kg than after 100 mg/kg. The highest drug concentrations were found in the liver and small intestine; concentrations were intermediate in lung, heart, and spleen, and lowest in brain. Less than 5% of the FAA dose was eliminated as unchanged drug in the stool. Total excretion of FAA as unchanged drug in the urine collected up to 96 h after drug treatment corresponded to 75% and 60% of the i.v. doses of 100 and 300 mg/kg, respectively. A minor fraction of FAA dose, corresponding to 1% and 6% of the two doses, was eliminated in the urine as a FAA glucuronide or sulfate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396145     DOI: 10.1007/bf00254180

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

2.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

Review 3.  Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

Authors:  P J O'Dwyer; D Shoemaker; D S Zaharko; C Grieshaber; J Plowman; T Corbett; F Valeriote; S A King; J Cradock; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.

Authors:  J Plowman; V L Narayanan; D Dykes; E Szarvasi; P Briet; O C Yoder; K D Paull
Journal:  Cancer Treat Rep       Date:  1986-05
  4 in total
  10 in total

1.  Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells.

Authors:  G Damia; G Tagliabue; P Allavena; M D'Incalci
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours.

Authors:  J Cummings; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Flavone acetic acid distribution in human malignant tumors.

Authors:  G Damia; A Freschi; R Sorio; A Braida; G Caruso; M Quaia; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours.

Authors:  M C Bibby; R M Phillips; J A Double
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

8.  Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.

Authors:  T S Maughan; R Ward; I Dennis; D J Honess; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

9.  Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.

Authors:  G Pratesi; C Manzotti; M Tortoreto; R A Audisio; F Zunino
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

10.  Anticoagulant treatment does not affect the action of flavone acetic acid in tumour-bearing mice.

Authors:  G Thurston; K A Smith; J C Murray
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.